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Thiazolides promote apoptosis in colorectal tumor cells
via MAP kinase-induced Bim and Puma activation
A Brockmann1,2, A Bluwstein1, A Kögel1, S May1,5, A Marx2,3, MP Tschan4 and T Brunner*,1,2
While many anticancer therapies aim to target the death of tumor cells, sophisticated resistance mechanisms in the tumor cells
prevent cell death induction. In particular enzymes of the glutathion-S-transferase (GST) family represent a well-known
detoxification mechanism, which limit the effect of chemotherapeutic drugs in tumor cells. Specifically, GST of the class P1
(GSTP1-1) is overexpressed in colorectal tumor cells and renders them resistant to various drugs. Thus, GSTP1-1 has become an
important therapeutic target. We have recently shown that thiazolides, a novel class of anti-infectious drugs, induce apoptosis in
colorectal tumor cells in a GSTP1-1-dependent manner, thereby bypassing this GSTP1-1-mediated drug resistance. In this study
we investigated in detail the underlying mechanism of thiazolide-induced apoptosis induction in colorectal tumor cells. Thiazolides
induce the activation of p38 and Jun kinase, which is required for thiazolide-induced cell death. Activation of these MAP kinases
results in increased expression of the pro-apoptotic Bcl-2 homologs Bim and Puma, which inducibly bind and sequester Mcl-1 and
Bcl-xL leading to the induction of the mitochondrial apoptosis pathway. Of interest, while an increase in intracellular glutathione
levels resulted in increased resistance to cisplatin, it sensitized colorectal tumor cells to thiazolide-induced apoptosis by
promoting increased Jun kinase activation and Bim induction. Thus, thiazolides may represent an interesting novel class of anti-
tumor agents by specifically targeting tumor resistance mechanisms, such as GSTP1-1.
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Glutathione-S-transferases (GSTs) represent a superfamily of
cellular phase II detoxification enzyme. Specifically, GSTs
catalyze the conjugation of electrophilic substances to the
tripeptid glutathione (GSH, γ-L-glutamyl-L-cysteinylglycine).
Thereby, hazardous metabolic products, xenobiotics and
oxidative stress products become rapidly neutralized by
GSTs, protecting cells from potentially damaging substances
and carcinogens. Consequently, GSTs have a critical role in
the detoxification of cells and inactivation of drugs.1,2 At the
present, seven classes of mammalian cytosolic GSTs are
known, whose expression is regulated in a tissue-specific
manner3–5 pointing toward a defined role of individual GSTs in
the biotransformation of drugs and reactive compounds in
diverse tissues.6,7
GSTs have a critical role in tumor therapy, as numerous
tumors overexpress various GSTs, which contribute to the
development of resistance to chemotherapeutic treatments.8,9
In particular, high expression levels of GST class pi (GSTP1-1)
have been reported in a wide range of solid tumors, such as
colon, breast, kidney, pancreas, lung, and ovarian cancer
cells, and lymphoma.10–12 The sensitivity of these tumors
toward chemotherapeutic drugs, such as cisplatin, doxorubi-
cin, and etoposide, is negatively affected by high expression
levels of GSTP1-1.13–17 Thus, overexpression of GSTP1-1 in
solid tumors limits the therapeutic effects of different che-
motherapeutic drugs via their GSTP1-1-mediated inactivation.
This observation identifies GSTs in general and GSTP1-1 in
particular as important therapeutic targets in the treatment of
solid tumors. Consequently, small molecular inhibitors of
GSTs have been developed in the past to modulate GST
activities and drug resistance of tumor cells, thereby sensitiz-
ing tumor cells to anticancer drugs. The therapeutic effect of
the competitive inhibitors ethacrynic acid (EA) was proven in a
clinical trial;18 however, long-term utility of EAwas limited by its
strong diuretic properties.19 A somewhat different approach
includes the GST-activated pro-drugs and the GSH analog
TLK199. TLK199 is metabolized and subsequently inhibits
GST activities, making it a more selective GST inhibitor.20
However, thus far experimental and clinical data on solid
tumors are missing.
Thiazolides are a novel class of anti-infectious drugs used
for the treatment of intestinal infection, and show a broad
activity against intestinal pathogens.21–24 The parent com-
pound nitazoxanide (NTZ; 2-(acetolyloxy)-N-(5-nitro-2-thiazo-
lyl)benzamide) is successfully used for the treatment of
Giardia lamblia and Cryptosporidium parvum infections.25–28
Though thiazolides generally have minimal side effects on
host tissue cells during therapeutic treatments,29 it was
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recently noticed that they promote apoptosis induction in
colorectal tumor cells, however, sparing non-transformed
cells.30 Of interest, while the bromo-thiazolide RM4819 (N-
(5-bromothiazol-2-yl)2-hydroxy-3-methylbenzamide) shows
only reduced anti-microbial activity, both NTZ and RM4819
promote cell death in colorectal tumor cells. This indicates that
the therapeutic targets of thiazolides are substantially different
in intestinal parasites and colorectal tumor cells. Subsequent
studies identified GSTP1-1 as a major RM4819-binding
partner in colorectal tumor cells.30 While it was initially thought
that thiazolides are inhibitors of GSTP1-1, it is presently
accepted that GSTP1-1 is required for thiazolide-induced cell
death induction. Interestingly, an N-acetyl-L-cysteine (NAC)-
induced increase in cellular GSH levels enhanced thiazolide-
induced cell death, whereas it lowered the sensitivity toward
chemotherapeutic drugs by promoting their GSTP1-1-
mediated inactivation.31 Thus, thiazolides appear to represent
a novel class of GSTP1-1-activated pro-drugs, activated likely
by conjugation to GSH, rather than GSTP1-1 inhibitors. This
makes thiazolides an interesting novel class of anti-tumor
drugs specifically targeting tumors with elevated levels of
GSTs, and GSTP1-1 an Achilles’ heel for the potential
therapeutic action of thiazolides. While thiazolides alone are
relatively slow and weak inducers of apoptosis in colorectal
tumor cells, they profoundly synergize with inducers of the
intrinsic apoptosis pathway, such as chemotherapeutic drugs,
as well triggers of the extrinsic pathway, such as TRAIL (TNF-
related apoptosis-inducing ligand).31
The mechanism of thiazolide-induced apoptosis and sensi-
tization of tumor cells to other apoptosis triggers is presently
incompletely understood, although GSTP1-1, the activation of
the MAP kinases, and the Bcl-2-regulated mitochondrial
apoptosis pathways appear to have a critical role in this
process.31 In this study we investigated in more detail the
underlying molecular signaling pathways leading to thiazolide-
induced cell death in colorectal tumor cells. We find that
activity of both the MAP kinases p38 and Jun kinase (JNK) is
critical for mediating thiazolide-induced apoptosis, as their
combined inhibition blocks cell death induction. In particular
JNK was found to be important for the induction and activation
of the downstream effectors of the Bcl-2 family, that is, the
BH3-only proteins Bim and Puma. Bim and Puma appear to
activate the mitochondrial pathway by interacting with and
neutralizing the anti-apoptotic Bcl-2 homolog Bcl-xL, and
inhibition of JNK prevented Bim and Puma induction,
interaction with Bcl-xL, and induction of apoptosis. Further-
more, thiazolides induced interaction of Bim with Mcl-1
and promote the degradation of Mcl-1. While an increase in
cellular GSH levels inhibited chemotherapy-induced apopto-
sis, it resulted in a more robust activation of JNK, Bim
induction, Mcl-1 degradation, and associated thiazolide-
induced cell death.
In summary, we here show that thiazolides are a novel group
of GSTP1-1-activated pro-drugs, which activate the mitochon-
drial apoptosis pathway at different levels. Given that GSTs
are highly overexpressed in numerous tumors and that GSTs
contribute to therapy resistance of these tumors, thiazolides
may become an interesting therapeutic option for the
treatment of chemoresistant tumor cells.
Results
Thiazolides induce JNK- and p38-dependent cell death.
The molecular structure of thiazolides consists of a thiazole-
ring and a benzene ring linked by an amide bond. We have
previously performed a structure-function study and shown
that changes of substituents in the benzene ring do not affect
the cell death-promoting activity of thiazolides, whereas
removal of the bromide atom from the thiazole ring, as in
compound 2, strongly reduces the activity.32 To investigate
the thiazolide-induced apoptosis signaling pathways, we
employed RM4819 as an active thiazolide, and compound 2
is inactive control substance to induce apoptosis in the
colorectal tumor cell lines Caco-2 and LS174T. Figure 1a
(Caco-2 cells) and Supplementary Figure 1 (LS174T cells)
show that RM4819 induced cell death in a dose-dependent
manner, whereas cells were almost insensitive to compound 2.
In contrast, the chemotherapeutic drug cisplatin promoted
cell death in both colorectal tumor cell lines.
Next, the ability of RM4819 and compound 2 in inducing
activation of the MAP kinases JNK and p38 was assessed.
JNK activation was observed at around 2 h and p38 activation
4 h after stimulation with RM4819. As expected from its lack of
apoptosis-promoting activity stimulation of cells with com-
pound 2 did not result in a detectable increase in MAP kinase
activation (Figure 1b). While RM4819-induced MAP kinase
activation was specific, though relatively slow and weak, the
control substance cisplatin induced a pronounced and
sustained activation of both, JNK and p38 (Figure 1b).
To address the relevance of JNK and p38 activation in
thiazolide-induced cell death, we employed pharmacological
inhibitors of JNK and p38. Interestingly, while inhibition of
either JNK or p38 only partially blocked RM4819-induced
apoptosis, only combined inhibition of both, JNK and p38
almost completely prevented cell death induction. This
indicates that both MAP kinases are involved in thiazolide-
induced cell death in Caco-2 cells.
Thiazolides modulate expression levels of Bcl-2 family
members. We have previously shown that thiazolides
induce apoptosis via the Bcl-2 family-orchestrated mitochon-
drial apoptosis pathway. Specifically, we have seen that
thiazolides induce the expression of Bim, which participates
in thiazolide-induced cell death.31 But likely other compo-
nents of the mitochondrial apoptosis pathway contribute to
the execution of thiazolide-induced apoptosis. To understand
whether and how thiazolides affect expression levels of
different pro- and anti-apoptotic Bcl-2 homologs, cells were
stimulated with RM4819, compound 2, and cisplatin as
control, and levels of Bim, Puma, Bcl-xL, and Mcl-1 were
assessed by western blotting. As found previously, we
observed an RM4819-induced increase in Bim levels already
2 h after stimulation. Of interest, after 4 and 6 h Bim levels
were not further induced but showed an increase in higher
molecular weight species of BimEL, indicative of Bim
phosphorylation.33–35 In marked contrast, only a minimal
increase in Bim expression over that of control treated cells
was observed in response to compound 2, with no apparent
induction of Bim phosphorylation. Cisplatin treatment resulted
in a strong increase in Bim expression, but not Bim
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phosphorylation. RM4819, but not compound 2 and cisplatin,
also induced a substantial increase in Puma expression
(Figure 2a and Supplementary Figure 2). While Bcl-xL levels
remained unaffected by the treatment of cells with the
different substances, a decrease of Mcl-1 expression was
noticed after stimulation of the cells with RM4819, but not with
compound 2 or cisplatin (Figures 2b and c). This finding was
also confirmed in other colorectal tumor cells (LS174T) and
for later time points (16 h) (Supplementary Figures 2a and b).
This RM4819-induced degradation of Mcl-1 is likely not a
consequence of caspase activation, as the pan-caspase
inhibitor zVAD failed to prevent Mcl-1 degradation, whereas
the proteosome inhibitor MG132 stabilized it (Supplementary
Figure 2c).
RM4819-induced apoptosis is dependent on Bim and
Puma. The profound increase in Bim and Puma expression
levels suggested that these BH3-only proteins might repre-
sent critical components in the activation of the mitochondrial
apoptosis pathway. To test this hypothesis Bim and Puma
were knocked down using lentiviral small hairpin RNA
constructs inducing RNA interference. Infection of both
Caco-2 and LS174T cells with specific lentiviruses resulted
in a profound decrease in Bim, resp. Puma expression
(Figures 3a and b). Control cells and cells with reduced Bim,
resp. Puma expression were then stimulated with the
thiazolides RM4819 and compound 2, or cisplatin as control.
As expected compound 2 failed to induce cell death, whereas
RM4819 induced a strong increase in apoptosis. Knockdown
of both Bim and Puma induced a significant reduction of
RM4819-induced cell death in Caco-2 and LS174T cells.
Similarly, cisplatin-induced cell death was also attenuated in
cells with downregulated Bim and Puma expression (Figures
3a and b), in agreement with previous observations.36
Figure 1 Thiazolide-induced cell death is JNK and p38-dependent. (a) Caco-2 cells were treated with indicated concentrations of RM4819, compound 2, cisplatin, or DMSO
as solvent control for 40 h. Cell death induction was calculated by an MTTassay. Mean values of triplicates± S.D. of a representative experiment are shown (n43). (b) Caco-2
cells were control treated (ctrl), or with thiazolides (20 μM), cisplatin (10 μg/ml), or DMSO (0.1%) for indicated time intervals. Phospho-JNK (p-JNK), phospho-p38 (p-p38), and
tubulin as a loading control were detected by western blotting. (c–e) Caco-2 cells were pretreated with JNK V inhibitor (2.5 μM) (c), p38 inhibitor (10 μM), (d) or the combination of
both (e) 1 h before stimulation with 20 μM RM4819 for further 40 h. Cell death induction was assessed by an MTTassay. Mean values of triplicates± S.D. of a representative
experiment are shown (n43). *Po0.01
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Since neither downregulation of Bim nor Puma alone
completely inhibited RM4819-induced cell death, and BH3-
only proteins often act in concert, we aimed at investigating
whether combined downregulation of Bim and Puma resulted
in a more pronounced inhibition of cell death. Control shRNA-
or Puma shRNA-infected Caco-2 cells were transfected with
control siRNA or siRNA against Bim. Knockdown efficiency for
these two BH3-only proteins was confirmed by western blot
and revealed efficient silencing of Bim and Puma (Figure 3c).
When cells were stimulated with increasing concentrations of
RM4819 a partial protection was seen in Bim and Puma single
knockdown cells. Importantly, combined knockdown of both
BH3-only further increased protection from RM4819-induced
cell death (Figure 3c), indicating that Puma and Bim cooperate
in inducing the mitochondrial apoptosis pathway.
Bim and Puma interact with pro-survival Bcl-2 members.
As at least one mechanism how BH3-only proteins promote
apoptosis is the binding to and neutralization of anti-apoptotic
Bcl-2 members,37 we addressed the question whether
thiazolides promote Bim and Puma binding to Bcl-xL and
Mcl-1. When Bcl-xL was immunoprecipitated a constitutive
binding of Bim and Puma was observed. Treatment of cells
with RM4819 and cisplatin seemed to further induce Bim
binding to Bcl-xL, whereas compound 2 failed to do so
(Figure 4a). More pronounced were the changes in the
binding of Puma to Bcl-xL. While only low levels of Puma
were bound to Bcl-xL in control, cisplatin- or compound 2-
treated cells, stimulation of cells with RM4819 resulted in a
strong increase in Puma binding to Bcl-xL. This is likely due to
the RM4819-induced increase in Puma expression (Figures
2a and 4a,Supplementary Figure 2). When BH3-only binding
to Mcl-1 was analyzed only minimal changes in Bim binding
were observed. In RM4819-stimulated cells even a reduced
co-immunoprecipitation of Bim was observed, likely due to
the fact that already lower levels of Bim were evident in cell
lysates at this time point after RM4819 stimulation (8 h), and
Bim might already being consumed and degraded during the
process of apoptosis induction. Furthermore, RM4819 also
resulted in the degradation of Mcl-1. In contrast, while Puma
was detectable in cell lysates and induced by RM4819,
no Puma binding to Mcl-1 was detected in these
co-immunoprecipitation experiments (Figure 4b). Thus,
RM4819-induced Puma appears to interact predominantly
with Bcl-xL.
JNK mediates Bim and Puma activation. As the MAP
kinases p38 and JNK have been found to be critically
involved in thiazolide-induced apoptosis in colorectal tumor
cells (Figures 1c and e),31 we next aimed at analyzing their
role in Bim and Puma induction and activation. Cells were
thus treated with RM4819 for different time points in the
presence or absence of JNK inhibitor. The presence of JNK
inhibitor appeared to slightly stabilize Mcl-1 levels in
untreated cells, but only minimally prevent its thiazolide-
induced degradation, whereas Bcl-xL levels remained unaf-
fected (Figure 5a and Supplementary Figure 3). It also had a
profound effect on thiazolide-induced Bim and Puma levels.
JNK inhibition resulted in decreased Bim levels in both control
treated and RM4819-treated cells, and inhibited RM4819-
induced Puma induction (Figure 5a and Supplementary
Figure 3). Inhibition of p38 had less pronounced effects on
Bim and Puma expression. Only minimally reduced Bim or
Puma levels were seen in cells treated with p38 inhibitor and
RM4819 (Supplementary Figure 4). Thus, Bim and Puma
expression appears to be regulated predominantly by JNK.
We next assessed how JNK inhibition would affect RM4819-
induced activation and binding of Bim and Puma to Bcl-xL and
Mcl-1. Even more pronounced than its effect on Bim
expression was the JNK inhibitor-induced inhibition of Bim
binding to Bcl-xL, in both control and RM4819-stimulated cells.
Whereas Puma inducibly bound to Bcl-xL inhibition of JNK
strongly attenuated Puma binding. As seen before no Puma
binding to Mcl-1 could be detected, whereas Bim binding to
Mcl-1 was also reduced upon inhibition of JNK (Figure 5c).
This indicates that JNK has an important role in the regulation
of Bim and Puma expression, and their activation and binding
to anti-apoptotic Bcl-2 family members.
Increase in intracellular GSH levels enhances thiazolide-
induced JNK activation and apoptosis induction. GSH is
an important anti-oxidant in cells. GSTs couple GSH to
xenobiotics and drugs, and thereby inactivate them.1,2 NAC is
a precursor of GSH, and treatment of cells with NAC leads to
increased intracellular GSH levels.31 We have been pre-
viously suggesting that GSTP1-1 may also couple GSH to the
pro-drug thiazolides, thereby generating a bioactive and pro-
apoptotic product, since treatment of Caco-2 cells with NAC
sensitized them to thiazolides, yet reduced the sensitivity to
cisplatin.31 This observation was confirmed in Figure 6a,
demonstrating enhanced thiazolide-induced cell death in
Figure 2 Changes in thiazolide-induced Bcl-2 family member expression. (a and
b) Caco-2 cells were treated with 20 μM thiazolides, 10 μg/ml cisplatin, or 0.1%
DMSO for 2, 4, and 6 h, and Bim and Puma (a), Mcl-1 and Bcl-xL (b) expression levels
were detected by western blot. (c) Mcl-1 and Bcl-xL expression levels were detected
8 h after treatment with complete medium as control, 0.1% DMSO, 20 μM RM4819 or
compound 2, or 10 μg/ml cisplatin. Tubulin served as a loading control
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Figure 3 Thiazolide-induced cell death is regulated by Bim and Puma. Caco-2 (a) and LS174T (b) cells were transduced with Bim- or Puma-targeting shRNA (shBim,
shPuma) or non-targeting shRNA (shControl). Bim and Puma knockdown efficiency was monitored by western blot (insets). Cells transduced with shControl, shBim, or shPuma
were treated with DMSO (0.1%), RM4819 (20 μM), or cisplatin (1 μg/ml) for 40 h. Cell death induction was calculated by an MTTassay. Mean values of triplicates±S.D. of a
representative experiment are shown (n43). *Po0.01 (c) Caco-2 cells transduced with shControl and shPuma were transiently transfection of Bim-targeting small interfering
RNA (siBim) or control siRNA (siNone). Silencing of both Bim and Puma was confirmed by western blotting. Cells were treated with 10-20 μM RM4819 or 0.1% DMSO for 40 h.
Cell death induction was assessed by an MTT assay. Mean values of triplicates± S.D. of a representative experiment are shown (n43)
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NAC-treated cells. We thus set to analyze the effect of NAC
on JNK activation, and Bim and Puma induction and
activation. When cells were treated with NAC and stimulated
with RM4819 an even more pronounced degradation of Mcl-1
was observed, whereas levels of Bcl-xL remained unaffected
(Figure 6b). Along these lines a strongly enhanced and
sustained activation of JNK was observed. In contrast, only
a minimal increase in p38 activation was observed
(Supplementary Figure 5b). Next the effect of NAC on Bim
expression and binding to Bcl-xL was assessed. NAC
treatment appeared to induce an increase in Bim protein
levels, and contribute also to the stabilization of Bim protein
expression after RM4819 treatment (Figures 6b and c). Along
these lines, a profound increase in Bim binding to Bcl-xL was
observed (Figure 6c), suggesting also an increase in Bim
activation. The relative NAC-mediated increase in Bim
expression was also confirmed on mRNA level, where co-
treatment with NAC and RM4819 leads to a threefold
increase in Bim expression (Figure 6d).
In contrast to Bim, no increase or rather a slight decrease in
Puma expression was seen, although JNK activation was
drastically increased (Supplementary Figures 5b and c), and a
contribution of JNK activity in the RM4819-induced Puma
expression has been shown above (Figure 5a). This may be
possibly explained by the antioxidant activity of NAC.
Treatment of cells with RM4819 leads to increase in
intracellular reactive oxygen species (ROS) (Supplementary
Figure 5a), which may also contribute to Puma induction,
Figure 5 JNK mediates Bim and Puma induction and activation. (a) Caco-2 cells
were pretreated with buffer control or JNK V inhibitor (2.5 μM) for 1 h before treatment
with 0.1% DMSO or 20 μM RM4819 for 2, 4 and 8 h. Mcl-1, Bcl-xL, Bim, and Puma
were detected by western blot. Tubulin served as a loading control. (b and c) Caco-2
cells were pretreated with JNK V inhibitor for 1 h, before stimulation with RM4819 or
DMSO for 8 h. Bcl-xL (b) and Mcl-1 (c) were immunoprecipitated, and Puma and Bim
were detected by western blotting. IgG, isotype control; HC, immunoglobulin heavy
chain; LC, immunoglobulin light chain
Figure 4 RM4819-induced binding of Bim and Puma to Bcl-xL and Mcl-1. Caco-2
cells were treated with 0.1% DMSO, 20 μM RM4819 or compund 2, or 10 μg/ml
cisplatin for 8 h. (a and b) Bcl-xL (a) and Mcl-1 (b) were immunoprecipitated and
interaction with Bim and Puma was confirmed by western blotting. In input controls
4% of the total lysates, resp. 8% of the precipitates were loaded. IgG, isotype control;
HC, immunoglobulin heavy chain
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possible via induction of DNA damage. ROS are, however,
efficiently scavenged by NAC and NAC-induced increased
levels of GSH. In line with this hypothesis, cisplatin-induced
JNK and p38 activation, known to be induced via ROS,38 was
also attenuated by NAC (Supplementary Fig. 5c).
Discussion
Current cancer therapy often targets specifically survival- and
cell death-regulating processes,39 for example by using
chemotherapeutic drugs. GSTs have an important function
in the detoxification of cells in general, and the detoxification of
tumor cells from such chemotherapeutic drugs in
particular.1,2,8,9 Coupling of drugs to GSH inactivates and
targets them for rapid secretion via bile or kidneys. Further-
more, more recently GSTs have also been found to sequester
MAP kinases and thereby affect cellular signaling processes,
such as apoptosis induction.40 It is thus not surprising that
GSTs are overexpressed in a large number of tumors.
Specifically, GSTP1-1 levels are increased in ovarian,
lung, breast, kidney, pancreas, and colon cancer, and
lymphomas,10–12 and limit chemotherapy.13–17
Given the important function of GSTs in detoxification and
tumor cell survival, GSTs have become important therapeutic
drug targets. EA is a potent GST inhibitor.18,41,42 However,
clinical trials have not been successful due to its massive
diuretic effects.19 TLK199 is another GST-activated GSTP1-1
inhibitor, which is currently in different clinical trials for the
treatment of myelodysplatic syndrome, with a similar mode of
action, that is, as a GSH-activated GST inhibitor.20 Various
aspects indicate that the here described thiazolides act
differently. Although we have initially seen that thiazolides
bind to GSTP1-1 and inhibit the enzymatic activity of GSTP1-1
in vitro, very likely this observation was based on substrate
competition. Indeed, we have seen later that enzymatic
GSTP1-1 activity is required for thiazolides to kill colorectal
tumor cells, and that increased GSH levels enhance thiazolide
activity31,32 (Figure 6a). Thus, very likely GSTP1-1 couples
GSH to thiazolides, and thereby generates active apoptosis-
promoting products. Furthermore, thiazolides sensitize tumor
cells to triggers of the mitochondrial (chemotherapeutic drugs)
and the extrinsic pathway (TRAIL).31 While high GSTP1-1
expression makes them very resistant to chemotherapeutic
drugs and metabolites, it renders the cells also more
susceptible to thiazolides. Thus, thiazolides bypass an
important tumor resistance mechanism.31 Last, but not least,
thiazolides are already successfully used in the clinic for the
treatment of intestinal infections24–28 and show very little side
effects on normal tissue cells. Given that thiazolides are well
tolerated, and sensitize tumor cells to chemotherapeutic
Figure 6 Increased GSH levels promote thiazolide-induced apoptosis. (a) Caco-2 cells were pretreated with 10 mM NAC for 1 h, before stimulation with RM4819 (10 μM),
cisplatin (10 μg/ml), or DMSO (0.1%) for 40 h. Cell death induction was monitored by an MTTassay. Mean values of triplicates±S.D. of a representative experiment are shown
(n43). *Po0.0001. (b) Caco-2 cells were pretreated with 10 mM NAC for 1 h, followed by stimulation with 0.1% DMSO or 20 μM RM4819 for times indicated. Phosphorylated
JNK (p-JNK), Bim, Mcl-1, Bcl-xL, and tubulin were detected by western blot. (c) Caco-2 cells were pretreated with 10 mM NAC for 1 h, and stimulated with 20 μMRM4819 or 0.1%
DMSO for 8 h. Interaction of Bim with Bcl-xL was assessed by immunoprecipitation and western blotting. IgG, isotype control; HC, immunoglobulin heavy chain. (d) Caco-2 cells
were pretreated with 10 mM NAC for 1 h, and stimulated with DMSO (0.1%) or RM4919 (20 μM) for 8 h. Bim mRNA expression was assessed by quantitative RT-PCR. Mean
values of experimental triplicates±S.D. of a representative experiment are shown (n43). *Po0.01. RQ, relative quantification
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drugs, the combined use of thiazolides with other anti-cancer
drugs may also allow to administer lower drug doses with
similar anti-tumor efficacy but reduced side effects on
tissue cells.
Though it is clear that GSTP1-1 converts the pro-drug
RM4819 to an active component, thus far the underlying
molecular processes causing cell death were not understood.
Here we now show that exposure of cells to thiazolides
induces MAPK activation, and that MAP kinase activation is
important for the execution of thiazolide-induced cell death.
Combined activation of JNK and p38 appears to promote the
transcriptional induction and possibly also activation of the
BH3-only proteins Bim and Puma. These two proteins bind
and neutralize Bcl-xL and Mcl-1, thereby promoting apoptosis.
Thiazolides not only induce neutralization of Bcl-xL and Mcl-1,
but also promoteMcl-1 degradation, which likely further lowers
the apoptosis resistance of tumor cells.
The induction and phosphorylation-induced activation of
Bim is likely directly mediated by JNK. JNK inhibition results in
reduced expression of Bim and reduced binding to Mcl-1.
When cells were stimulated with active thiazolides, but not with
inactive thiazolides, a shift of Bim to higher molecular weight
forms is observed, likely representing JNK-mediated Bim
phosphorylation (Figure 2a). Thus, JNK appears to regulate
Bim at the transcriptional and post-translational level. Also
thiazolide-induced Puma expression is likely controlled by
JNK, as inhibition of JNK leads to reduced thiazolide-induced
expression levels of Puma (Figure 5a) and reduced Puma
binding to Bcl-xL (Figure 5b). At present the mechanism of
thiazolide-induced MAP kinase activation is unclear; however,
the recently described pathway, in which GSTP1-1 sequesters
and inactivates JNK,40 which may be reversed by thiazolides,
has to be explored in further detail.
While thiazolides are not extremely potent pro-apoptotic
drugs, they potently synergize with other apoptosis triggers,
such as TRAIL and cisplatin.31 They appear to bring cells into
a sensitized stage where little activation by other triggers is
required to cause massive apoptosis induction.31 Thus,
thiazolides may be useful for future combination therapy with
conventional chemotherapeutic drugs. In addition, thiazolides
alone are well tolerated by tissue cells, possibly because not
all cells have high GSTP1-1 levels, promoting the activation of
thiazolides. Furthermore, we have previously made the
intriguing observation that thiazolides are only active in
proliferating cells,30 although the underlying mechanism is
presently not understood. Yet, the combination of restricted
GSTP1-1 expression and proliferation status may protect
tissue cells and bone marrow cells from thiazolide-induced
destruction, while it renders tumor cells, specifically colorectal
tumor cells, highly sensitive to thiazolide-induced apoptosis.
Though clinical trials have to prove this concept and the overall
usefulness of thiazolides in the treatment of colorectal tumors,
the present data suggest that thiazolides may represent an
interesting novel therapeutic approach for the treatment of this
tumor entity.
Materials and Methods
Cell lines and reagents. The colon cancer cell lines Caco-2 (ATCC HTB-37)
and LS174T (ATCC CL-188) were obtained from American Type Culture Collection
(ATCC) and cultured in Iscove's Modified Dulbecco's Medium (IMDM) supplemented
with 10% fetal calf serum (FCS), 4 mM L-glutamine, and 50 μg/ml gentamicin (all
from Sigma-Aldrich, Steinheim, Germany). Cells were cultured at 37 °C and 5%
CO2 in a humidified atmosphere. Cisplatin and 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazoliumbromid (MTT) were obtained from Sigma-Aldrich and DMSO
from ROTH (Karlsruhe, Germany). JNK V inhibitor and p38 inhibitor SB202190
were purchased from Calbiochem (Darmstadt, Germany), the dye 6-carboxy-2′, 7′-
dichlorodihydrofluorescein diacetate (carboxy-H2DCFDA) from Life Technologies
(Darmstadt, Germany). Thiazolides RM4819 and compound 2 were synthesized in-
house as described earlier.32 Compounds were kept as 20 mM stock solutions
in DMSO.
MTT assay. Cell viability was measured by using an MTT assay. Caco-2 and
LS174T cells were seeded into 96-well plates at 5–8 × 103 cells/well. After overnight
attachment, cells were treated with thiazolides, cisplatin, or DMSO as a control for
40 h. In some experiments JNK and/or p38 inhibitors were added 1 h before
apoptosis induction. In some assays cells were treated with 10 mM N-acetyl-L-
cysteine (NAC, Sigma-Aldrich) for 1 h to increase intracellular GSH levels. At the
end of the experiment cell culture medium was discarded and replaced with 0.5 mg/
ml MTT solution, dissolved in complete medium. Plates were incubated under cell
culture condition for an additional 1-2 h. After MTT reduction to purple formazan, the
MTT solution was discarded and replaced with 100 μl DMSO to dissolve the
formazan products. Plates were incubated for 15 min in a dark box at room
temperature. After gently mixing of the plates, the intensity of the colored solution
was quantified by measuring the absorbance at λ= 562 nm on an ELISA reader
(Tecan, Crailsheim, Germany). Cell death induction (%) was calculated as
100 × (1− (OD exp. mean value (− substrate blank)/OD control mean value
(− substrate blank)).
Bim and Puma knockdown in Caco-2 and LS174T cells using
lentiviruses. HEK293T cells were seeded into 10 cm petri-dish and co-
transfected with the packaging plasmid pCMVdeltaR8.2, the envelope plasmid
pMD2-VSV-G and pLKO-based plasmid containing shRNA against human Bim
(NM_138621.X-541s1c1 and NM_138621.3-559s21c1) and Puma (NM_014417.2-
1318s1c1 and NM_014417.2-785s1c1) (pMission, Sigma-Aldrich) using Roti®-Fect
Plus (ROTH). Plasmid SHC002 (Sigma-Aldrich) served as non-target control. After
24 h, medium was changed with complete Dulbecco’s Modefied Eagle’s Medium
(DMEM) containing 10% FCS and 50 μg/ml gentamicin for further 24 h. In parallel,
Caco-2 and LS174Twere seeded into six-well plates (1.8–2.2 ×105 cells/well). Next
day, viruses in the supernatant were collected and filtered through a 0.45 μm filter
and charged with 8 μg/ml polybrene (Sigma-Aldrich). Target cells were then
transduced with the virus mixture in a 1 : 2 dilution for 1 day. Stable cells were
selected using 3 μg/ml puromycin. Silencing of Bim and Puma was verified by
western blotting.
Double knockdown of Bim and Puma in Caco-2 cells. For double
knockdown experiments, Bim expression in control shRNA or Puma shRNA-
transduced Caco-2 cells was silenced using Bim siRNA (L-004383-02) or control
siRNA (D-001820-01) (Dharmacon, siGenome SMARTpool). The cells were seeded
into six-well plates (1.8 × 106) and transfected with siRNAs for 24 h using
Lipofectamin®2000 (Life Technologies, Carlsbad, CA) as transfection reagent, as
done previously.31,34 Afterward, cells were transferred to a 96-well plate (5 × 103
cells/well) and used for cytotoxicity assays. In parallel, Bim and Puma knockdown
was verified 48 h post transfection by western blot.
Western blot. Caco-2 or LS174T cells were seeded into 10 cm petri-dish
(2 × 106) and treated with thiazolides (20 μM), cisplatin (10 μg/ml), DMSO (0.1%), or
with complete medium as control for 0, 2, 4, and 6 h and additional 8 h. In some
experiments, Caco-2 cells were pretreated with JNK inhibitor (2.5 μM) or with p38
inhibitor (10 μM) or with NAC (10 mM) for 1 h. before treatment with RM4819,
cisplatin, or DMSO for up to 16 h. Cells were then lysed in NP40-lysis buffer
(150 mM NaCl, 50 mM Tris pH 7.6, 1 mM EDTA and 1% NP-40) and cell lysates
were separated on a denaturing 12% SDS-PAGE gel. After transfer to
polyvinylidene difluoride membranes (PVDF) (Roche, Mannheim, Germany),
Mcl-1, Bcl-xL, Bim, Puma, phospho-JNK, phospho-p38, or tubulin as loading
control were detected using specific antibodies (anti-Mcl-1 from eBioscience
(Frankfurt, Germany); anti-Bcl-xL (54H6), anti phospho-SAPK/JNK (Thr183/Tyr185)
(81E11), anti-phopho–p38 MAPK (Thr180/Tyr182) (D3F9), anti-Puma (D30C10)
from Cell Signaling Technology (Davers, MA, USA); anti-Bim, anti-α-Tubulin from
Sigma-Aldrich). Proteins were detected using horse radish-coupled secondary
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antibodies and enhanced chemiluminescence on an Image Quant LAS 4000 (GE
Healthcare, Braunschweig, Germany).
Immunoprecipitation. Caco-2 cells were seeded into 10-cm petri dishes
(2 × 106 cell/well) and treated with thiazolides (20 μM), cisplatin (10 μg/ml), or
DMSO (0.1%) for 8 h. In some experiments cells were additionally pretreated with
2.5 μM JNK inhibitor or 10 mM NAC for 1 h. Cells were then harvested by
trypsinization, washed once with PBS and lysed using 500 μl NP-40 lysis buffer
containing a protease inhibitor cocktail. Cell lysates were then precleared using
Sepharose protein G beads (GE Healthcare, Freiburg, Germany), and Mcl-1 and
Bcl-xL were immunoprecipitated using Sepharose protein G beads coupled with
specific antibodies or isotype controls for 24 h at 4 °C under constant agitation. After
washing proteins were eluted by boiling in SDS-PAGE loading buffer and resolved
on a 12% SDS-PAGE. Proteins detected by western blot as described above.
Detection of mRNA expression. Caco-2 cells were seeded into 10-cm
petri dishes (2 × 106 cell/well). After attachment, cells were pretreated with 10 mM
NAC for 1 h to increase the GSH level before treatment with RM4819 (20 μM) or
DMSO (0.1%) for further 8 h. Cells were harvested, lysed in PeqGOLD TriFast
(PeqLab, Erlangen, Germany) RNA isolation reagent and RNA was isolated
according to the manufacturer's protocol. One microgram of RNA was reverse
transcribed and cDNAs were used for quantification of gene expression by
quantitative PCR using FASTSYBR Green Master Kit and a StepOnePlus Real time
PCR system (Applied Biosystems, Foster City, CA, USA). The following primers
were used: human Bim forward 5′-ATG AGA AGA TCC TCC CTG CT-3′ and
reverse 5′-AAT GCA TTC TCC ACA CCA GG-3′, GAPDH forward 5′-ATG GAG
AAG GCT GGG GCT CA-3′ and reverse 5′-AGT GAT GGC ATG GAC TGT GGT
CAT-3′ to normalize the gene expression by GAPDH expression levels.
Reactive oxygen species (ROS) measurement. Caco-2 cells were
incubated with 10 μM H2DCFDA for 1 h, before stimulation with 20 μM thiazolides,
1 mM H2O2, or 0.1% DMSO for 15 min. In the presence of ROS, the H2DCFDA
molecule becomes oxidized and fluorescents at Ex/Em: ~ 492–495/517–527 nm.
The mean fluorescence intensity (MFI) was analyzed by flow cytometry on a LSR
Fortessa Cell Analyzer using FACS Diva software (BD Biosciences, Heidelberg,
Germany).
Statistics. Statistical differences were analyzed using Prism 5 software and a
multiple t-test. For experiments described in Supplementary Figure 4a, a one-way
ANOVA with Dunnett’s multiple comparison post-test was performed.
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